Navigation Links
TELITHROMYCIN - the proven effective new drug for cap

Community acquired pneumonia other wise known as CAP has been a therapeutic challenge to most of the practising physicians. This is mainly due to the growing resistance of the bacteria causing them to the available antibiotics.

Telithromycin (Ketek), a new ketolide antibiotic, is highly effective in treating patients with pneumococcal bacteraemia associated with community-acquired pneumonia (CAP). This is a breakthrough in the field of anti microbials as pneumococcal resistance is on the rage. Dr. Thomas M. File, Jr., of Northeastern Ohio University of Medicine, Rootstown, commented that, "Currently clinicians who perceive their patients to be at risk for infection with resistant pathogens are relying on one or two classes of antimicrobials. This results in increased pressure on those classes ", and this infact is responsible for the resistance strains of this group of bacteria.

The efficacy of the drug was assessed by five clinical trials and clinical and biological outcomes was noted. Blood samples were taken before and after the therapy for both aerobic and anaerobic culture. It was found that, the overall clinical cure rate with telithromycin was 89.5% after 7 to 11 days of therapy.

Telithromycin has recently been approved by the US Food and Drug Administration for the treatment of CAP, acute bacterial exacerbation of chronic bronchitis (ABECB), and acute bacterial sinusitis (ABS) and is marketed by Aventis Pharma.
'"/>




Page: 1

Related medicine news :

1. Partial-Breast Irradiation an Unproven Therapy
2. New drug proven to tackle Type 2 Diabetes
3. Morning after pill effective up to five days after having unprotected sex
4. Distraction therapy found very effective in postoperative patients
5. Digital mammography proves effective
6. Treatment for pre-menstrual syndrome is ineffective
7. Cost-effective antibiotics for sinusitis treatment
8. An effective way to treat angina
9. Fluoride proves effective against fractures
10. Meningitis C vaccine a cost-effective success
11. An effective drug for lung cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/27/2017)... IL (PRWEB) , ... March 27, 2017 , ... ... systems, recently received the CE Certificate of Conformity for the Smart System® 20/20. ... or exceed the highest industry standards and specifications such as ANSI, ISO and ...
(Date:3/27/2017)... ... March 27, 2017 , ... American Veterinarian™, the leading multimedia ... medicine, announces the launch of Veterinarian’s Money Digest™, a business and financial resource ... of American Veterinarian™. , “We look forward to launching Veterinarian’s Money ...
(Date:3/27/2017)... Orion, Michigan (PRWEB) , ... March 27, 2017 ... ... results. The comprehensive weight management program at Women’s Excellence will help patients ... initial evaluation and physical exam. The specialists at Women's Excellence will measure ...
(Date:3/27/2017)... ... 27, 2017 , ... EpiGentek , a Farmingdale, NY-based ... RNA methylation “gold rush” with their established portfolio of optimized assay kits that ... or m6A , RNA methylation has received a new burst in interest ...
(Date:3/27/2017)... ... March 27, 2017 , ... The Association ... chain professionals, will hold their first Northeast Regional AHVAP Meeting. For 2017, Dr. ... “Increasingly, supply chain and value analysis professionals have a ‘seat at the table’ ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... 27, 2017 On Friday, benchmark ... Composite closed the trading session up 0.19%; the Dow ... 500 was down 0.08%. US markets made broad based ... day in green. Pre-market today, Stock-Callers.com reviews these four ... (NASDAQ: WMGI), Amedica Corporation (NASDAQ: AMDA), MiMedx Group Inc. ...
(Date:3/27/2017)... Calif. , March 27, 2017  Impax Laboratories, ... has appointed Paul M. Bisaro as Impax,s ... the Company,s Board, effective March 27, 2017. Mr. Bisaro ... served as Interim President and Chief Executive Officer since ... of generic and branded pharmaceutical experience, Mr. Bisaro, 56, ...
(Date:3/27/2017)... , March 27, 2017 Arena Pharmaceuticals, Inc. ... on developing novel, small molecule drugs across multiple therapeutic areas, ... Chief Executive Officer, will present a corporate update at the ... 3:40pm ET.  The conference will take place April 4-5, 2017 ... New York , NY.  A live ...
Breaking Medicine Technology: